GlassScriptPhysician profile
Jennifer Laing
NPI 1790711919
$1,280.88
in general payments reported to CMS, 2019-2025
23 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $120 · 2021: $261 · 2022: $175 · 2023: $139 · 2024: $57.61 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $348.75 | 2021-2025 | |
| Viiv Healthcare Company | $125.01 | 2025 | Apretude |
| Lilly USA, LLC | $110.40 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $105.68 | 2019-2022 | |
| Ibsa Pharma INC. | $84.16 | 2020-2021 | |
| Smith+Nephew, INC. | $74.52 | 2019-2025 | Oasis, Grafix Pl, Pico |
| Otsuka America Pharmaceutical, INC. | $66.26 | 2022-2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $43.51 | 2021-2025 | Breztri, Airsupra |
| Axsome Therapeutics, INC. | $43.22 | 2025 | Auvelity |
| Opko Pharmaceuticals, LLC | $35.73 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $29.46 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.66 | 2025 | Gattex |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.47 | 2024 | Caplyta |
| Medline Industries LP | $20.03 | 2020 | |
| Glaxosmithkline, LLC. | $18.27 | 2024 | Trelegy Ellipta, Arexvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $17.64 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.47 | 2021 | |
| Allergan, INC. | $16.80 | 2019 | |
| Collegium Pharmaceutical, INC. | $16.70 | 2025 | Jornay Pm |
| Astellas Pharma US INC | $16.22 | 2025 | Veozah |
| Bioventus LLC | $15.22 | 2022 | |
| Reprise Biomedical, INC. | $14.58 | 2025 | Miro3d |
| Mylan Specialty L.P. | $13.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Laing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.